Final Development Stage For Prolia Reflects Amgen's Eye On Advertising
Executive Summary
Amgen's latest round of studies for the osteoporosis drug Prolia (denosumab) reflects the closing stage of the development program and shows how the company is laying groundwork for an advertising campaign - or at least a convincing argument for insurance coverage
You may also be interested in...
Inflamed Language: FDA Sends Harsh Warning Letter To Allergan For Acne Drug
Allergan gets slammed for Aczone Gel promotional claims that FDA says are backed by data "not even nominally statistically significant."
Amgen's Mixed Advisory Committee Votes On Prolia Still Offer A Good Start
The Reproductive Health Drugs Advisory Committee backs Prolia's use to treat osteoporosis in postmenopausal women and bone loss in men undergoing hormone ablation therapy for prostate cancer - though not the largest indication of osteoporosis prevention as well as a REMS.
Denosumab Approval Is “Highly Likely,”– Interview With Amgen’s Perlmutter
In a Jan. 26 interview, Amgen Executive VP for Research and Development Roger Perlmutter talks about denosumab, follow-on biologics and how Amgen is avoiding the size-related innovation drought that many big pharma companies now face.